The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 29, 2016
Filed:
Mar. 06, 2015
K. Stephen Suh, Hackensack, NJ (US);
Andre Goy, New York, NY (US);
K. Stephen Suh, Hackensack, NJ (US);
Andre Goy, New York, NY (US);
Hackensakc University Medical Center, Hackensack, NJ (US);
Abstract
The described invention comprises methods for predicting recurrence of Hodgkin Lymphoma (HL) and poor clinical outcome in a Hodgkin Lymphoma (HL) subject. The methods comprise providing a sample from the HL subject and a sample from a good clinical outcome control subject; isolating total RNA comprising Fibroblast Growth Factor-2 (FGF2) and Syndecan-1 (SDC1) RNA from the sample from the HL subject and from the sample from the good clinical outcome control subject; amplifying the total RNA; measuring a level of expression of the FGF2 and the SDC1 RNA in the HL subject and in the good clinical outcome control subject; and comparing the level of expression of the FGF2 and the SDC1 RNA expressed by the HL subject with the level of expression of the FGF2 and the SDC1 RNA expressed by the good clinical outcome control subject. An increased level of expression of the FGF2 RNA and the SDC1 RNA expressed by the HL subject compared to the level of expression of the FGF2 RNA and the SDC1 RNA expressed by the good clinical outcome control subject is indicative of recurrence of HL or poor clinical outcome for the HL subject. The described invention further comprises a method of detecting evidence of metastatic Hodgkin lymphoma in a Hodgkin Lymphoma (HL) subject by measuring an increased level of expression of CD30, FGF2 and SDC1 RNA in an HL subject compared to a good clinical outcome control subject.